Epigenetic Therapy Ties MYC Depletion to Reversing Immune Evasion and Treating Lung Cancer
Michael J. Topper(Johns Hopkins University), Stephen B. Baylin(Johns Hopkins University), Meredith L. Stone(Roswell Park Comprehensive Cancer Center), Matthew D. Hellmann(AstraZeneca (United States)), Katherine B. Chiappinelli(George Washington University), Michelle Vaz(Johns Hopkins University), Matthew Ballew(Johns Hopkins University), Valsamo Anagnostou(Johns Hopkins University), Cynthia A. Zahnow(Johns Hopkins University), Phuoc T. Tran(University of Chicago Medical Center), Christina E. DeStefano Shields(Johns Hopkins University), Jessica Hicks(Johns Hopkins University), Noushin Niknafs(Johns Hopkins University), Alyssa Wenzel(Johns Hopkins University), Pamela L. Strissel(Universitätsklinikum Erlangen), Victor E. Velculescu(Johns Hopkins University), Ray-Whay Chiu Yen(Johns Hopkins University), Reiner Strick(Friedrich-Alexander-Universität Erlangen-Nürnberg)
Cited by 521
Related Papers
Cancer Genome Landscapes
|Science|2013|8k
Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors
|Science|2017|5.4k
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k
Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses
|Science|2008|4k
The Consensus Coding Sequences of Human Breast and Colorectal Cancers
|Science|2006|3.2k